News | Contrast Media | September 07, 2017

Administration looks to solicit opinions and recommendations on regulatory approaches to administration of GBCAs

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents

September 7, 2017 — The U.S. Food and Drug Administration (FDA) held a meeting of the Medical Imaging Drugs Advisory Committee (MIDAC) on Sept. 8 to discuss regulatory approaches for use of gadolinium-based contrast agents (GBCAs).

In a statement, the administration said, “FDA has convened this advisory committee to seek opinions and recommendations on regulatory approaches to the issue of gadolinium retention in the brain and other body organs following administration of gadolinium based contrast agents (GBCAs). The evidence indicating retention following the use of GBCAs has led to concerns that gadolinium retention may cause adverse reactions, if not immediately then at some later date. FDA will ask the committee to focus on scientific facts; observational data; nonclinical, clinical and epidemiological study findings; post-marketing adverse event reports; and regulatory requirements in considering its responses to FDA questions.”

The statement continued, “FDA’s approach has been educational: alerting the public and clinicians to the retention phenomenon but not issuing any restrictions on use because toxic effects in humans have not been established.

We now seek advice from the committee on the strength of the scientific evidence that would support potential regulatory actions such as labeling changes in relation to gadolinium retention. We also seek suggestions on the design of further epidemiologic and other studies to investigate potential adverse events associated with gadolinium retention in humans...”

The statement concluded, “…It is important to note that FDA’s intention in convening the current Advisory Committee is to solicit advice limited in scope to safety issues surrounding post-GBCA gadolinium retention in patients with normal renal function.”

The FDA’s decision to convene the MIDAC on this topic follows the May 22, 2017 update to its previous Drug Safety Communication entitled “FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.”

For more information: www.fda.gov

 

Related Content on MRI Gadolinium Retention in the Brain

FDA: No Harm in MRI Gadolinium Retention in the Brain

Recent Trends and Developments in Contrast Media

VIDEO: MRI Gadolinium Contrast Retention in the Brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

Related Content

News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
Feature | Contrast Media

The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% ...

Time May 03, 2022
arrow
Sponsored Content | Case Study | Contrast Media Injectors

Product Indications and Use: CLARISCAN (gadoterate meglumine) is a gadolinium-based contrast agent indicated for ...

Time May 03, 2022
arrow
News | Contrast Media

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
Sponsored Content | Videos | Contrast Media

With the use of contrast agents and radiotracers on the rise, GE Healthcare has seen increases in demand across their ...

Time February 23, 2022
arrow
Feature | Contrast Media Injectors | By Melinda Taschetta-Millane

Contrast media injectors are used to inject contrast agents to enhance the blood and perfusion in tissues. There have ...

Time January 19, 2022
arrow
News | Contrast Media

December 30, 2021 — The "Global Contrast Media Market Size, Share & Trends Analysis Report by Product Type (Iodinated ...

Time December 30, 2021
arrow
News | Contrast Media Injectors

December 13, 2021 — Qaelum NV announced that they enter into a strategic partnership with ulrich GmbH & Co. KG in Ulm to ...

Time December 13, 2021
arrow
Subscribe Now